The Relationship Between the Neutrophil-Lymphocyte Ratio and In-Stent Restenosis in Patients With Femoropopliteal Chronic Total Occlusions

Abstract

We investigated the relationship between the neutrophil-lymphocyte ratio (NLR) and in-stent restenosis (ISR) in patients with femoropopliteal chronic total occlusions (CTOs). The study enrolled 180 patients who had undergone successful stenting treatment for femoropopliteal CTO. Patients with ISR were subsequently classified into 2 groups: early-ISR (within 1 year) and late-ISR (after 1 year). The clinical characteristics, angiographic data, and follow-up data were recorded. The baseline NLR was significantly higher in the early-ISR group than that in the non-ISR group [3.96(2.14) and 3.33(2.73), p = .04]. Receiver operating characteristic curve analysis suggested an optimum early ISR NLR cutoff point of 3.62, which showed a sensitivity and specificity of 73.4% and 80.4%, respectively (area under the curve: 0.707, 95% confidence interval: 0.603-0.792, P < .001). A subgroup analysis was performed based on the NLR value (<3.62 vs ≥3.62). In the NLR ≥3.62 subgroup, the incidence of early ISR was higher than that of late ISR (P < .01). In the multivariate analysis, NLR ≥3.62 was independently and positively associated with a higher risk of early ISR. In conclusion, NLR is independently associated with early ISR after stent implantation in patients with femoropopliteal CTO.

Keywords

neutrophil-lymphocyte ratio in-stent restenosis femoropopliteal artery chronic total occlusion

Get full access to this article

View all access options for this article.

References

Norgren

Hiatt

Dormandy

. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5–S67.

Razzouk

Aggarwal

Gorgani

Babaev

. In-stent restenosis in the superficial femoral artery. Ann Vasc Surg. 2013;27(4):510–524.

Inoue

Croce

Morooka

Sakuma

Node

Simon

. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv. 2011;4(10):1057–1066.

Joviliano

Piccinato

Dellalibera-Joviliano

Moriya

Évora

. Inflammatory markers and restenosis in peripheral percutaneous angioplasty with intravascular stenting: current concepts. Ann Vasc Surg. 2011;25(6):846–855.

Balta

Celik

Mikhailidis

. The relation between atherosclerosis and the neutrophil-lymphocyte ratio. Clin Appl Thromb Hemost. 2016;22(5):405–411.

Bhat

Afari

Garcia

. Neutrophil lymphocyte ratio in peripheral vascular disease: a review. Expert Rev Cardiovasc Ther. 2016;14(7):871–875.

Arbel

Shacham

Ziv-Baran

. Higher neutrophil/lymphocyte ratio is related to lower ejection fraction and higher long-term all-cause mortality in ST-elevation myocardial infarction patients. Can J Cardiol. 2014;30(10):1177–1182.

Cildag

Koseoglu

. The relationship between neutrophil-lymphocyte ratio and primary patency of percutaneous transluminal angioplasty in hemodialysis arteriovenous fistula stenosis when using conventional and drug-eluting balloons. Cardiovasc Intervent Radiol. 2016;39(12):1702–1707.

Küçük

Kocayiğit

Günel

Düzenli

. Neutrophil-to-lymphocyte ratio in occlusive vascular diseases: the literature review of the past 10 years. World J Emerg Med. 2016;7(3):165–172.

10.

Balli

Taşolar

Çetin

. Use of the neutrophil to lymphocyte ratio for prediction of in-stent restenosis in bifurcation lesions. Eur Rev Med Pharmacol Sci. 2015;19(10):1866–1873.

11.

Verdoia

Barbieri

Di Giovine

. Neutrophil to Lymphocyte ratio and the extent of coronary artery disease: Results from a large cohort study. Angiology. 2016;67(1):75–82.

12.

Hirsch

Haskal

Hertzer

. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113(11):e463–e654.

13.

Tosaka

Soga

Iida

. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59(1):16–23.

14.

Bleda

de Haro

Varela

Acin

. C-reactive protein and endovascular treatment of lower limb peripheral artery disease: an independent prognostic factor. J Endovasc Ther. 2015;22(2):233–239.

15.

Inoue

Koyama

Miyata

Shigematsu

. Pathogenetic heterogeneity of in-stent lesion formation in human peripheral arterial disease. J Vasc Surgery. 2002;35(4):672–678.

16.

Iida

Uematsu

Soga

. Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses. Catheter Cardiovasc Interv. 2011;78(4):611–617.

17.

Hong

Jeong

Lim

. Relation of soft plaque and elevated preprocedural high-sensitivity C-reactive protein levels to incidence of in-stent restenosis after successful coronary artery stenting. Am J Cardiol. 2006;98(3):341–345.

18.

Choi

Hong

Ahn

Park

Jeong

. Relationship between neutrophil-to-lymphocyte ratio and plaque components in patients with coronary artery disease: virtual histology intravascular ultrasound analysis. J Korean Med Sci. 2014;29(7):950–956.

19.

Davies

Bismuth

Saad

. Implications of in situ thrombosis and distal embolization during superficial femoral artery endoluminal intervention. Ann Vasc Surg. 2010;24(1):14–22.

20.

Hua

. Incidence, risk factors, treatment and prognosis of popliteal artery embolization in the superficial femoral artery interventions. PLoS One. 2014;9(9):e107717.

21.

Chen

Qin

Baeyens

. Endothelial-to-mesenchymal transition drives atherosclerosis progression. J Clin Invest. 2015;125(12):4514–4528.

22.

Zhang

Chang

Wang

. Effect of polyelectrolyte film stiffness on endothelial cells during endothelial-to-mesenchymal transition. Biomacromolecules. 2015;16(11):3584–3593.

23.

Evrard

Lecce

Michelis

. Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability. Nat Commun. 2016;7:11853.

24.

Tanindi

Ekici

Töre

. Do pre-procedural laboratory parameters predict drug-eluting stent restenosis?. Turk Kardiyol Dern Ars. 2015;43(5):457–464.